{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:45:14Z","timestamp":1789148714446,"version":"build-2803163510"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Allergic bronchopulmonary aspergillosis (ABPA) is a disease characterized by severe disability with recurrent wheezing and shortness of breath. The current recommended therapy is daily oral corticosteroids +\/\u2212 oral antifungal therapy. Despite this, many patients continue to have severe symptoms, and others require fairly high daily oral corticosteroid dosing to achieve control, which in turn may induce the well-known effects of long term steroid use. The anti-interleukin drugs have been reported to help improve daily symptoms and reduce steroid requirements. Much of the literature highlights the benefit of omalizumab. We present a case of dupilumab as add-on therapy in a patient with ABPA, which allowed us to reduce daily steroid dosage.<\/jats:p>","DOI":"10.1093\/omcr\/omaa029","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T16:12:48Z","timestamp":1619626368000},"source":"Crossref","is-referenced-by-count":15,"title":["Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis"],"prefix":"10.1093","volume":"2021","author":[{"given":"Muhammad","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Pulmonary and Critical Care Section, Baystate Medical Center - University of Massachusetts Medical School, Springfield, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5126-6747","authenticated-orcid":false,"given":"O\u2019Neil","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pulmonary and Critical Care Section, Baystate Medical Center - University of Massachusetts Medical School, Springfield, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"2021070812422961200_ref1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/cea.12354","article-title":"Pattern recognition pathways leading to a Th2 cytokine bias in allergic bronchopulmonary aspergillosis patients","volume":"45","author":"Becker","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"2021070812422961200_ref2","first-page":"CD010288","article-title":"Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","volume":"11","author":"Jat","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2021070812422961200_ref3","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.anai.2018.01.009","article-title":"Cytokine-targeting biologics for allergic diseases","volume":"120","author":"Lawrence","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2021070812422961200_ref4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ppul.23612","article-title":"Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients","volume":"52","author":"Nov\u00e9-Josserand","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"2021070812422961200_ref5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.rmed.2016.11.019","article-title":"Beneficial effects of omalizumab therapy in allergic bronchopulmonary aspergillosis: a synthesis review of published literature","volume":"122","author":"Li","year":"2017","journal-title":"Respir Med"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2021\/4\/omaa029\/37430025\/omaa029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2021\/4\/omaa029\/37430025\/omaa029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T20:51:10Z","timestamp":1625777470000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omaa029\/6255675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omaa029","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4]]},"published":{"date-parts":[[2021,4,1]]},"article-number":"omaa029"}}